<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116047">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968668</url>
  </required_header>
  <id_info>
    <org_study_id>16816</org_study_id>
    <nct_id>NCT01968668</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in Japanese subjects with type 2 diabetes mellitus and the
      clinical diagnosis of Diabetic Nephropathy( DN) using a multi-center, randomized, adaptive,
      double-blind, placebo-controlled, parallel-group design.

      Primary objective of the study is investigate the change of Urinary Albumin to Creatine
      Ratio (UACR) after treatment with different oral doses of BAY94-8862 given once daily from
      baseline to Visit 8 (Day 90)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change of urinary albumin-to creatinine ratio</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum potassium concentration</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>BAY94-8862 (1.25 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY94-8862 (2.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY94-8862 (5 mg )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY94-8862 (7.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY94-8862 (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY 94-8862 (15 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY 94-8862 (20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY94-8862</intervention_name>
    <description>1.25 mg BAY94-8862 tablet once daily in the morning</description>
    <arm_group_label>BAY94-8862 (1.25 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY94-8862</intervention_name>
    <description>2.5 mg BAY94-8862 tablet once daily in the morning</description>
    <arm_group_label>BAY94-8862 (2.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY94-8862</intervention_name>
    <description>5 mg BAY94-8862 tablet once daily in the morning</description>
    <arm_group_label>BAY94-8862 (5 mg )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY94-8862</intervention_name>
    <description>7.5 mg BAY94-8862 tablet once daily in the morning</description>
    <arm_group_label>BAY94-8862 (7.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY94-8862</intervention_name>
    <description>10 mg BAY94-8862 tablet once daily in the morning</description>
    <arm_group_label>BAY94-8862 (10 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet once daily in the morning</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 94-8862</intervention_name>
    <description>15 mg BAY 94-8862 tablet once daily in the morning</description>
    <arm_group_label>BAY 94-8862 (15 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 94-8862</intervention_name>
    <description>20 mg BAY 94-8862 tablet once daily in the morning</description>
    <arm_group_label>BAY 94-8862 (20 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese subjects with type 2 diabetes mellitus and a clinical diagnosis of DN
             (Diabetic Nephropathy) treated with at least the minimal recommended dose of an
             Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blocker
             (ARB)

          -  Subjects with a clinical diagnosis of Diabetic Nephropathy (DN) based on at least 1
             of the following criteria:

               -  Persistent very high albuminuria defined as Urinary Albumin to Creatine Ratio
                  (UACR) of &gt;/=300 mg/g (&gt;/=34 mg/mmol) in 2 out of 3 first morning void samples
                  and estimated glomerular filtration rate (eGFR) &gt;/=30 mL/min/1.73 m2 but &lt;90
                  mL/min/1.73 m2 Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) or

               -  Persistent high albuminuria defined as UACR of &gt;/=30 mg/g but &lt;300 mg/g (&gt;/=3.4
                  mg/mmol but &lt;34 mg/mmol) in 2 out of 3 first morning void samples and eGFR&gt;/=30
                  mL/min/1.73 m2 but &lt;90 mL/min/1.73 m2 (CKD-EPI)

          -  Serum potassium &lt;/=4.8 mmol/L at both the run-in visit and the screening visit

        Exclusion Criteria:

          -  Non-diabetic renal disease (confirmed by biopsy)

          -  Known bilateral clinically relevant renal artery stenosis (&gt;75%)

          -  Glycated hemoglobin(HbA1c) &gt;12% at the run-in visit or the screening visit

          -  UACR &gt;3000 mg/g (339 mg/mmol) in any of the urinary first morning void samples at the
             run-in visit or screening visit

          -  Hypertension with mean sitting systolic blood pressure (SBP) &gt;/=180 mmHg or mean
             sitting diastolic blood pressure (DBP) &gt;/=110 mmHg at the run-in visit or mean
             sitting SBP &gt;/=160 mmHg or mean sitting DBP &gt;/=100 mmHg at the screening visit

          -  Subjects with a clinical diagnosis of heart failure with reduced ejection fraction
             (HFrEF) and persistent symptoms (New York Heart Association class II-IV) at the
             run-in visit

          -  Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or
             potassium-sparing diuretic
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-0815</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>456-0058</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Saijo</city>
        <state>Ehime</state>
        <zip>793-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <zip>080-0848</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-0828</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Koga</city>
        <state>Ibaraki</state>
        <zip>306-0232</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsuchiura</city>
        <state>Ibaraki</state>
        <zip>300-0835</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-0812</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kahoku-gun</city>
        <state>Ishikawa</state>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakaide</city>
        <state>Kagawa</state>
        <zip>762-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumisano</city>
        <state>Osaka</state>
        <zip>598-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Yao</city>
        <state>Osaka</state>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Katsushika</city>
        <state>Tokyo</state>
        <zip>125-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BAY94-8862</keyword>
  <keyword>MR antagonist</keyword>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Japanese patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
